AngioDynamics, Inc. ANGO

Health CareHealthcare Equipment & SuppliesUnited States of America

Last close 12.35 USD on Nov 1, 2026, −6.6% year to date

Quant rating

Quant rating C Rank 368 of 565 in Health Care

Growth D 415 of 565
Valuation B 199 of 565
Quality A 80 of 565
Revisions D 528 of 565
Momentum C 388 of 565

Wall Street consensus Buy (2.00)Average target 19.75 USD +59.9%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 504M
Enterprise value: 476M
52-week range: 9.41 – 16.29
3-year range: 5.27 – 16.29
Dividend yield: –
Beta (5 years): 0.26
Shares outstanding: 42.1M
Next earnings: Jan 4, 2027

About the company

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters.

Growth and profitability

Growth and profitability by fiscal year
	2026	2025	2024	2023	2022	5Y avg
Revenue (mil)	320	292	304	339	316	–
Revenue growth	9.5%	−3.8%	−10.3%	7.1%	8.7%	1.9%
EPS (basic, normalized)	−0.15	−0.15	−0.38	−0.06	0.00	–
EPS growth	–	–	–	–	–	–
Gross margin	54.6%	53.9%	50.9%	51.4%	52.4%	52.7%
Net margin	−11.5%	−11.6%	−60.7%	−15.5%	−8.4%	−21.5%
ROE	−20.8%	−17.5%	−63.1%	−13.1%	−6.1%	−24.1%

Balance sheet, last quarter
Cash & short-term investments (mil)	34.0
Current ratio	2.40x
Long-term debt (mil)	5.3
Net debt (mil)	−28.3
Total equity (mil)	164
Net debt / equity	−0.17x
Net debt / EBITDA	−1.56x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2026 actual	320	+9.5%	1.5x	18.2	–	26.2x	−0.15	0.0%	−82.3x
2027	338	+5.5%	1.4x	14.8	−18.6%	32.2x	−0.28	−83.3%	−44.9x
2028	355	+5.1%	1.3x	26.9	+81.8%	17.7x	−0.10	+61.8%	−117.6x
2029	375	+5.6%	1.3x	36.8	+36.8%	12.9x	0.22	+309.5%	56.1x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2027	338	+0.2%	+0.2%	+2.5%	−0.28	−3.1%	−3.1%	−75.5%
2028	355	0.0%	0.0%	+2.0%	−0.10	−133.3%	−133.3%	−250.0%
2029	375	0.0%	0.0%	+2.0%	0.22	0.0%	0.0%	+15.8%

Earnings surprises EPS beat in 3 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	May 2024	Aug 2024	Nov 2024	Feb 2025	May 2025	Aug 2025	Nov 2025	Feb 2026	May 2026	Aug 2026
Sales reported (mil)	71.0	67.5	72.8	72.0	80.2	75.7	79.4	78.4	86.6	80.9
Sales mean (mil)	70.9	67.9	70.9	70.3	74.3	72.7	76.3	76.8	80.4	80.5
Surprise	+0.2%	−0.7%	+2.7%	+2.4%	+7.9%	+4.1%	+4.1%	+2.2%	+7.7%	+0.5%
EPS reported	−0.06	−0.11	−0.04	0.03	−0.03	−0.10	0.00	0.02	−0.07	−0.04
EPS mean	−0.17	−0.15	−0.11	−0.13	−0.12	−0.12	−0.10	−0.11	−0.09	−0.11
Surprise	+64.0%	+25.0%	+63.6%	−123.1%	+75.0%	+14.9%	+100.0%	−118.2%	+22.2%	+64.7%

Peer comparison Healthcare Equipment & Supplies

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
ANGO AngioDynamics, Inc.	504M	−1.56x	−11.5%	3.10x	−44.9x	−117.6x	32.2x	17.7x
4543 TERUMO CORPORATION	22.6B	0.27x	12.0%	2.13x	26.9x	18.7x	12.4x	10.5x
MDT Medtronic PLC	123.5B	1.99x	13.2%	2.46x	16.2x	15.1x	12.8x	12.3x
BSX Boston Scientific Corporation	60.8B	2.03x	14.4%	2.44x	13.2x	13.3x	11.4x	11.4x
TFX Teleflex Incorporated	5.9B	3.99x	2.9%	2.04x	19.4x	12.8x	16.4x	13.7x
MMSI Merit Medical Systems Inc	5.2B	0.65x	8.5%	2.96x	19.8x	18.5x	13.0x	11.8x
Mean		1.23x	6.6%	2.52x	8.4x	−6.6x	16.4x	12.9x
Median		1.32x	10.2%	2.45x	17.8x	14.2x	12.9x	12.1x

Technical analysis

1M−22.8%
3M−16.4%
1Y−2.4%
3Y+88.5%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, AngioDynamics, Inc., fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Total revenue	320	292	304	339	316	291
Cost of revenue	145	135	149	165	150	134
Gross profit	175	158	155	174	166	157
Selling, general & administrative expenses	157	145	144	144	134	117
Research & development	29.4	26.2	31.5	29.9	30.7	36.4
Depreciation/amortization	10.7	10.3	13.0	18.8	19.5	18.1
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	17.6	15.6	158	30.2	9.0	20.2
Other operating expenses	0	0.3	0.4	2.3	1.2	0.1
Operating income	−39.9	−40.0	−192	−51.2	−28.5	−35.3
Net interest income (expense)	−0.3	1.0	1.6	−2.7	−0.7	−0.9
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	3.9	4.9	−0.8	−0.6	−0.8	0.1
Net income before taxes	−36.3	−34.0	−192	−54.4	−29.9	−36.1
Provision for taxes	0.4	0	−7.3	−2.0	−3.4	−4.5
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	−36.7	−34.0	−184	−52.4	−26.5	−31.5
Extraordinary items	–	–	–	–	–	0
Net income	−36.7	−34.0	−184	−52.4	−26.5	−31.5
EBIT, normalized	−22.3	−24.3	−34.3	−21.0	−19.4	−15.1
EBITDA, normalized	0.6	1.5	−6.5	9.9	9.9	10.9
Basic EPS, normalized	−0.15	−0.15	−0.38	−0.06	0.00	–

Balance sheet in millions of USD, fiscal years

Balance sheet, AngioDynamics, Inc., fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Assets
Cash & short-term investments	53.9	55.9	76.1	44.6	28.8	48.2
Receivables	48.5	43.1	50.0	52.8	52.3	35.4
Total inventory	52.4	62.0	60.6	55.3	51.4	48.6
Prepaid expenses	8.6	7.3	6.6	4.6	10.8	8.7
Other current assets	0	0	0	6.2	0	0
Total current assets	163	168	193	164	143	141
Property, plant & equipment	32.1	36.1	41.5	49.5	52.0	46.5
Goodwill	–	–	0	159	201	201
Intangibles	67.2	69.1	77.4	111	152	169
Long-term investments	–	–	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	4.4	6.6	5.6	49.2	4.0	3.8
Total assets	267	280	318	533	553	561
Liabilities
Accounts payable	31.5	33.3	37.8	40.4	28.0	19.6
Payable/accrued	–	–	–	–	–	–
Accrued expenses	40.2	35.1	36.8	28.5	37.4	37.9
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	0.4	0.4	–	–	–	–
Other current liabilities	2.6	7.4	16.6	14.8	8.9	0.1
Total current liabilities	74.7	76.2	91.2	83.8	74.3	57.6
Long-term debt	5.4	5.8	0	49.8	25.0	20.0
Minority interest	–	–	–	–	–	–
Other liabilities	16.2	15.2	20.9	20.7	28.9	44.4
Total liabilities	96.3	97.2	112	154	128	122
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	0.4	0.4	0.4	0.4	0.4	0.4
Additional paid-in capital	636	621	610	599	587	574
Retained earnings (accumulated deficit)	−466	−429	−395	−211	−158	−132
Treasury stock	−7.4	−7.4	−5.7	−5.7	−5.7	−5.7
Other equity	7.7	−2.0	−4.4	−4.7	1.4	3.2
Total equity	171	183	206	378	424	439
Total liabilities & shareholders' equity	267	280	318	533	553	561

Cash flow statement in millions of USD, fiscal years

Cash flow statement, AngioDynamics, Inc., fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Operating activities
Net income	−36.7	−34.0	−184	−52.4	−26.5	−31.5
Depreciation, depletion & amortization	23.0	25.8	27.7	30.9	29.3	25.9
Deferred taxes	0.1	−1.0	−8.0	−2.3	−3.7	−4.8
Non-cash items	19.4	13.2	122	31.0	14.8	25.5
Changes in working capital	−2.7	−14.1	14.4	−7.0	−21.0	9.1
Cash from operations	3.1	−10.1	−28.2	0.1	−7.2	24.1
Investing activities
Capital expenditures	−2.6	−4.5	−5.8	−4.4	−4.3	−5.2
Other investing cash flows	−3.4	−5.7	129	−5.4	−15.0	−8.5
Cash from investing	−5.9	−10.2	124	−9.7	−19.3	−13.7
Financing activities
Financing cash flow items	0	−5.7	−15.0	−0.8	0	0
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	0.6	5.4	−49.2	26.2	7.7	−17.0
Cash from financing	0.6	−0.3	−64.2	25.4	7.7	−17.0
Foreign exchange effects	0.3	0.4	0.1	0	−0.5	0.3
Net change in cash	−2.0	−20.2	31.4	15.8	−19.3	−6.3
Free cash flow	0.5	−14.6	−33.9	−4.3	−11.5	18.9

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 1, 2026 after market close.